Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized, double-blind, placebo-controlled study of SHR0302 tablets in adults with alopecia areata
CTR20213405Phase 3Completed
- Sponsor
- Reistone Biopharma
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ivarmacitinib in alopecia areata, sponsored by Reistone Biopharma. Started Jan 2022; status: completed.
02
Drugs
ivarmacitinib
03
Conditions
alopecia areata
Beyond the preview
Go deeper on CTR20213405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20213405.